S&P 500
(0.03%) 5 088.80 points
Dow J
(0.16%) 39 132 points
Nasdaq
(-0.28%) 15 997 points
Oil
(-2.60%) $76.57
Gas
(-8.66%) $1.582
Gold
(0.74%) $2 045.80
Silver
(0.84%) $22.98
Platinum
(0.11%) $906.50
USD/EUR
(0.04%) $0.924
USD/NOK
(0.33%) $10.53
USD/GBP
(-0.12%) $0.789
USD/RUB
(0.62%) $93.60

Realtime updates for NLS Pharmaceutics AG [NLSP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated23 Feb 2024 @ 15:58

-2.46% $ 0.400

Live Chart Being Loaded With Signals

Commentary (23 Feb 2024 @ 15:58):
Profile picture for NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders...

Stats
Today's Volume 29 040.00
Average Volume 534 339
Market Cap 14.27M
EPS $0 ( 2023-08-04 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.800
ATR14 $0.0080 (2.00%)

NLS Pharmaceutics AG Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NLS Pharmaceutics AG Financials

Annual 2022
Revenue: $0
Gross Profit: $-11 408.00 (0.00 %)
EPS: $-0.880
Q2 2023
Revenue: $0
Gross Profit: $-5 704.00 (0.00 %)
EPS: $-0.200
Q4 2022
Revenue: $0
Gross Profit: $-5 704.00 (0.00 %)
EPS: $-0.290
Q2 2022
Revenue: $0
Gross Profit: $-5 704.00 (0.00 %)
EPS: $-0.540

NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

AboutLive Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators